[Phase II clinical trial of the radioactive strontium (89Sr) chloride agent, SMS. 2P for pain palliation in patients with prostate cancer with bone metastases].
The phase II clinical trial of a strontium (89Sr) chloride agent (SMS. 2P) was performed in 9 patients with painful bone metastases secondary to prostate cancer. After an intravenous administration, 89Sr circulated in the plasma and was rapidly cleared. Urinary excretion varied widely among the patients. No serious acute side effects were observed. A mild transient increase in pain was reported by 4 patients 2-4 days after administration, two of whom complained of mild nausea or vomiting. All symptoms improved and never became a clinical problem. There were some abnormal hematological parameters. In particular, a decrease in the platelet level seemed to be a marrow suppression due to 89Sr irradiation. It is difficult to discriminate between the effects of 89Sr and the progress of the disease using tumor markers. The pain level improved within 2 weeks after administration and the effect continued for at least 8 weeks, which improved the quality of life for these patients.
Kimura
Y
Y
Department of Radiology, Ehime University School of Medicine.
Hamamoto
K
K
Suzuki
K
K
Yokoyama
K
K
Hisada
K
K
Kasagi
K
K
Konishi
J
J
Ichiya
Y
Y
Masuda
K
K
Kubo
A
A
D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010148:Intractable Pain / Q000188:drug therapy*; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000473:pathology*; D013324:Strontium / Q000008:administration & dosage*
C025700:strontium chloride; D013324:Strontium